Statera Biopharma (NASDAQ:STAB) versus Palvella Therapeutics (NASDAQ:PVLA) Critical Analysis

Statera Biopharma (NASDAQ:STAB) and Palvella Therapeutics (NASDAQ:PVLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Risk and Volatility

Statera Biopharma has a beta of 0.1, meaning that its share price is 90% less volatile than the S&P 500. Comparatively, Palvella Therapeutics has a beta of 0.1, meaning that its share price is 90% less volatile than the S&P 500.

Earnings and Valuation

This table compares Statera Biopharma and Palvella Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Statera Biopharma	N/A	N/A	N/A	N/A	N/A
Palvella Therapeutics	$42.81 million	6.13	-$24.54 million	($12.10)	-1.96

Statera Biopharma has higher earnings, but lower revenue than Palvella Therapeutics.

Profitability

This table compares Statera Biopharma and Palvella Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Statera Biopharma	N/A	N/A	N/A
Palvella Therapeutics	N/A	-80.93%	-59.55%

Analyst Recommendations

This is a breakdown of current ratings for Statera Biopharma and Palvella Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Statera Biopharma	0	0	0	0	0.00
Palvella Therapeutics	0	0	7	1	3.13

Palvella Therapeutics has a consensus target price of $46.29, indicating a potential upside of 95.13%. Given Palvella Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Palvella Therapeutics is more favorable than Statera Biopharma.

Insider & Institutional Ownership

40.1% of Palvella Therapeutics shares are held by institutional investors. 5.5% of Statera Biopharma shares are held by insiders. Comparatively, 20.5% of Palvella Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Palvella Therapeutics beats Statera Biopharma on 7 of the 9 factors compared between the two stocks.

About Statera Biopharma

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado.

About Palvella Therapeutics

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.